Medical research for good reason is investigating why the immune system sometimes goes dormant while on other occasions it carries out rogue attacks on healthy cells and tissue.
The system that fights infections and other health threats inexplicably can mount autoimmune attacks resulting in many diseases including Type 1 diabetes, lupus and multiple sclerosis. On the contrary, the immune system also can become inactive against cancer.
Why it stops doing what it should do, and does what it shouldn’t, represents one of the biggest puzzles in medicine. And solving those puzzles is what UPMC and the University of Pittsburgh hope to accomplish at the newly announced UPMC Immune Transplant and Therapy Center in Bloomfield.
UPMC’s commitment of $200 million will allow researchers to take broad-based approaches to understanding the complexities of diseases and better identify drug targets. And one key goal is understanding exactly how cancer protects itself against an immune response.
Environmental protection
Finding out how the tumor blocks the immune system could lead to ways to regenerate the immune response against malignancies.
The immune system includes dendritic cells, which regulate what organisms the immune system destroys, with T cells and B cells generally serving as the soldiers that kill bacteria, viruses, fungi and other agents that pose health threats.
“The tumor micro-environment is a complex organization of many cell types, all of which have different functions,” said Dario A. Vignali, leader of the Cancer Immunology Program at the UPMC Hillman Cancer Center and vice-chair of the University of Pittsburgh School of Medicine’s Department of Immunology.
“Some are trying to get rid of the tumor, and others are supporting the tumor. They are often working against each other. It’s a complexity that our research is trying to unravel to identify new therapeutic targets. We are trying to manipulate the tumor environment and improve the immune response to the tumor,” he said.
The pharmaceutical industry tends to focus on the quarterback, or one key target, “but we don’t even know what the field looks like or what yard line they’re on, so our approach is holistic to understand what the entire field looks like,” he said.
Adding to the complexity is the fact that each cancer is different. Even the same cancer type varies by patient, explaining why there are different responses to treatments. New immunological cancer therapies have shown success, but their life-saving benefits only extend to 20 percent to 40 percent of patients, research has shown.
Greg M. Delgoffe, an assistant professor of immunology at Pitt with his own research team and laboratory, said tumors not only detect the presence of T cells but also can turn them off by removing their fuel or nutrient source, leaving them in states of exhaustion. In that sense, the battle becomes “a war of attrition” that the cancer usually wins without successful treatments.
“Our studies suggest that the metabolic makeup of the tumor micro-environment has critical influence on the immune response to cancer,” the Delgoffe website states.
Key is understanding the entire system tumors use to protect themselves, rather than focus on each individual participant.
“There are now far more resources to look at many targets within the tumor environment more broadly and expansively than we were able to do previously, and we hope that this will be truly game-changing,” said Mr. Vignali, who holds a doctorate in immunology and infectious diseases.
Reversing autoimmunity
Similarly, Mark J. Shlomchik, chair of Pitt School of Medicine’s Department of Immunology, and his team is working on understanding what prompts autoimmune attacks against one’s own cells, with dendritic cells as the current focus of his work.
Future treatments could involve destruction of dendritic cells that enter organs where they initiate flare ups in lupus and multiple sclerosis — and potentially in other autoimmune diseases.
“I like to extract themes across many diseases,” he said. “If it is happening in one disease, then it could be similar to what’s happening in others.”
Following another line of research, Dr. Shlomchik also is working to clone T cells in large numbers to reintroduce them to the patient to kill cancer.
As it turns out, each immune cell is different, much like the human fingerprint or snowflake. Those differences allow cells to attack such a wide variety of infections or foreign agents, all of which also are vastly different. For example, he said, many different T-cell variations are necessary to fight influenza, given the multiple variations of the virus.
By capturing the unique part of DNA in each T cell, “the cells can be cloned, immortalized and expanded,” Dr. Shlomchik said. Their reintroduction in high volumes could overwhelm the tumor’s defense mechanism and lead to tumor destruction.
“One of the spectacular things about the human immune system is its incredible diversity of T cells and B cells with their unique receptors, each person literally has billions of receptors,” Dr. Mark Shlomchik said.
Other key partners in Pitt/UPMC immunology research are Robert Ferris, director of the UPMC Hillman Cancer Center, and Warren Shlomchik, director of Hematopoietic Stem Cell Transplant and Cell Therapy at UPMC and Mark Shlomchik’s brother.
Overall, Dr. Mark Shlomchik said that Mr. Vignali — “one of the world leaders in understanding the tumor micro-environment” — along with other teams at the center will be working to solve different parts of the same complex question: “How T cells attack tumors.”
David Templeton: dtempleton@post-gazette.com or 412-263-1578. Twitter: @templetoons. The Delgoffe website is available at http://www.delgoffe-lab.com.






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.